Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ferro Completes Sale of Pharma Business | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ferro Completes Sale of Pharma Business

PLI Holdings gains Pfanstiehl Labs for $17M plus earn-out payments

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ferro Corp. has completed the sale of its pharmaceuticals business, Pfanstiehl Laboratories, to PLI Holdings, an affiliate of Med Opportunity Partners, for $16.9 million in cash and an earn-out incentive of as much as $8 million based on earnings targets. Ferro’s pharmaceuticals business had revenues of $2.4 million in 2012.
 
The sale is part of Ferro’s strategy to divest non-core businesses and drive earnings growth and profitability from its core Performance Materials and Performance Chemicals businesses.
 
“The sale of our pharmaceuticals business is another important milestone in our value creation strategy. The Ferro portfolio now is more fully concentrated in our core technologies in coatings and color and glass science, polymer science, and organic synthesis,” said Peter Thomas, interim president and chief executive officer of Ferro. We will remain focused on improving return on invested capital and cash flow by streamlining operations, reducing operating costs, and pursuing select growth opportunities. We are energized by the progress we’re making and committed to reaching our value creation objectives.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters